Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
RenovoRx, Inc. reports news on targeted oncology drug delivery, the commercialization of RenovoCath®, and clinical development of its TAMP™ therapy platform. The company is a life-sciences issuer developing localized cancer therapies and commercializing RenovoCath, a patented FDA-cleared drug-delivery device used for temporary vessel occlusion and chemotherapeutic drug infusion.
Recurring updates cover RenovoCath adoption at U.S. cancer centers, intellectual-property protection for the device, financing activity, financial results, and presentations of clinical or pharmacologic data. News also tracks IAG, the investigational intra-arterial gemcitabine product candidate delivered via RenovoCath, including disclosures tied to the TIGeR-PaC trial in locally advanced pancreatic cancer and orphan drug designations for pancreatic and bile duct cancer.
RenovoRx (Nasdaq: RNXT) announced expansion of commercial adoption of its FDA-cleared RenovoCath device from five active U.S. cancer centers in September 2025 to nine as of Jan 20, 2026, including City of Hope Cancer Center and Moffitt Cancer Center. The RenovoCath device enables the company’s TAMP™ localized chemotherapy delivery approach and is being integrated into oncology programs while related physician interviews and patient stories were publicized. RenovoRx reported approximately $900,000 in sales through September 2025 and says it built a dedicated commercial team by end of 2025 to accelerate adoption. Ongoing Phase III TIGeR-PaC trial sites are not counted among current commercial customers but could convert after full enrollment in H1 2026.
RenovoRx (Nasdaq: RNXT) announced that CEO Shaun Bagai will present at the AlphaNorth Capital Event on January 16-18, 2026 in Nassau, Bahamas. Mr. Bagai will provide updates on commercial adoption of RenovoCath (an FDA-cleared targeted drug-delivery device) and progress in the Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine for locally advanced pancreatic cancer (LAPC). He will also discuss a post-marketing observational registry collecting real-world safety and survival data across solid tumors and support for capital-efficient investigator-initiated trials in pancreatic cancer.
Investor one-on-one meetings can be requested via KCSA Strategic Communications.
RenovoRx (Nasdaq: RNXT) announced new pharmacokinetic (PK) and pharmacodynamic (PD) data from a Phase III TIGeR-PaC sub-study presented at ASCO GI 2026. The 16-patient sub-study compared intra-arterial gemcitabine (IAG) delivered via the TAMP therapy platform (11 patients) to standard IV gemcitabine (5 patients).
Key findings: IAG showed reduced systemic gemcitabine levels, increased inactive metabolite levels, and a correlation between higher metabolite levels and reduced CA 19-9 biomarker. The company says this profile may improve local potency and lower systemic side effects while the TIGeR-PaC trial continues to enroll and evaluates overall survival.
RenovoRx (Nasdaq: RNXT) announced acceptance of a clinical data abstract at the ASCO Gastrointestinal Cancers Symposium 2026 for a pharmacokinetic/pharmacodynamic sub-study of the Phase III TIGeR-PaC trial.
The sub-study, led by Dr. Paula Novelli, compares intra-arterial gemcitabine delivered via RenovoCath (IAG) to standard intravenous gemcitabine in locally advanced pancreatic cancer and reports decreased systemic drug levels consistent with a reduced clinical side-effect profile for the localized TAMP therapy approach.
The poster (Abstract 732, Poster Board K2) will be presented on January 9, 2026 at Moscone West, San Francisco, during Poster Session B.
RenovoRx (Nasdaq: RNXT) announced that CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference on December 9, 2025 at 12:30 P.M. ET. The presentation will cover commercial progress and market adoption of RenovoCath, recent clinical and scientific program updates, and support for investigator‑initiated trials.
The company reported year‑to‑date revenue of approximately $900,000 through September 30, 2025, and will discuss the ongoing Phase III TIGeR‑PaC trial and a post‑marketing registry capturing real‑world safety and effectiveness data. A replay and webcast will be available on the company investor site.
RenovoRx (Nasdaq: RNXT) announced that CEO Shaun Bagai will present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20, 2025 at 2:00 PM ET.
He will review commercial progress for RenovoCath, report year-to-date revenue of approximately $900,000 (as of Sept 30, 2025), and summarize clinical programs including the ongoing Phase III TIGeR-PaC trial for intra-arterial gemcitabine in locally advanced pancreatic cancer, a post-marketing registry capturing real-world safety and effectiveness data, and investigator-initiated studies in borderline resectable and oligometastatic pancreatic cancer. The presentation will cover adoption trends, market traction, and the TAMP therapy platform. Webcast access is provided on the company's investor relations site.
RenovoRx (Nasdaq: RNXT) reported third-quarter 2025 results on November 13, 2025, highlighting early commercial traction for its FDA-cleared RenovoCath device and progress on its Phase III TIGeR-PaC trial.
Key figures: Q3 revenue $266,000, year-to-date revenue ~$900,000, cash $10.0 million as of September 30, 2025, and Q3 net loss $2.9 million. The company expanded approved RenovoCath customers from five to 14 centers in 2025 and expects TIGeR-PaC enrollment to complete in early 2026 with final data in 2027.
RenovoRx (Nasdaq: RNXT) announced the appointment of Timothy Donahue, MD, a UCLA pancreatic surgery and translational oncology expert, to its Scientific Advisory Board on November 6, 2025. Dr. Donahue is Director of UCLA’s Agi Hirshberg Center for Pancreatic Diseases, Chief of the Division of Surgical Oncology, holds the Garry Shandling Chair in Pancreatic Surgery, and leads an NIH-funded research laboratory.
He performs high-volume pancreatic surgery, directs integrated induction-plus-surgery programs for locally advanced and borderline resectable pancreatic cancer, and endorsed RenovoRx’s targeted delivery platform, Trans-Arterial Micro-Perfusion (TAMP™).
RenovoRx (Nasdaq: RNXT) announced that CEO Shaun Bagai will participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20, 2025 in New York.
Mr. Bagai will provide an update on RenovoCath commercialization, discuss latest developments from the ongoing Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine delivered via RenovoCath for locally advanced pancreatic cancer, and review a recently launched post-marketing observational registry tracking long-term safety and survival outcomes for patients treated with RenovoCath.
RenovoRx (Nasdaq: RNXT) will host its Q3 2025 financial results and business highlights conference call on November 13, 2025 at 4:30 p.m. ET. Management is expected to discuss RenovoCath commercialization, progress in the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, and the PanTheR Post‑Marketing Registry Study evaluating long‑term safety and survival for patients treated with RenovoCath.
Investors can join by phone (1-877-407-4018 U.S. or 1-201-689-8471 international) or via webcast at https://ir.renovorx.com/news-events/ir-calendar-events. A Q&A will follow the presentation. A dial‑in replay is available through November 27, 2025 (1-844-512-2921 U.S. or 1-412-317-6671 international; replay PIN 13756201), and the recording will be posted on the investor relations website.